Adagene (ADAG) Retained Earnings (2019 - 2026)
Adagene (ADAG) posted quarterly Retained Earnings of -$328785.0 billion for Q4 2025, down 5.66% year-over-year from -$348507.0 billion in Q4 2024, and down 101272697.48% quarter-over-quarter from -$324.7 million in Q2 2025.
Adagene (ADAG) Retained Earnings (2019 - 2026) Analysis & Trends
Adagene (ADAG) has reported Retained Earnings for 7 consecutive years, with -$328785.0 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Retained Earnings fell 5.66% year-over-year to -$328785.0 billion; the TTM figure through Dec 2025 stood at -$328785.0 billion (down 5.66% YoY), while the FY2025 annual figure was -$328785.0 billion, down 5.66% from the prior year.
- Retained Earnings declined to -$328785.0 billion in Q4 2025 per ADAG's latest filing, from -$324.7 million in the prior quarter.
- Across five years, Retained Earnings topped out at $336.1 million in Q4 2021 and bottomed at -$328785.0 billion in Q4 2025.
- Historically, Retained Earnings has averaged -$166590.8 billion across 5 years, with a median of -$242640.6 billion in 2022.
- Annual changes were most pronounced in 2021 — Retained Earnings soared 418.11% — and 2022, when it tumbled 158545499.39%.
- Adagene's Retained Earnings stood at $336.1 million in 2021, then tumbled by 77002527.59% to -$258805.1 billion in 2022, then decreased by 7.32% to -$277751.5 billion in 2023, then retreated by 12.03% to -$311175.6 billion in 2024, then slipped by 5.66% to -$328785.0 billion in 2025.
- Business Quant data shows ADAG's Retained Earnings at -$328785.0 billion in Q4 2025, -$324.7 million in Q2 2025, and -$311175.6 billion in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Adagene | 310.54 Mn | 310.54 Mn | - | 436.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 436.77 Mn |
| Dec 31, 2025 | -328,785.00 Bn |
| Jun 30, 2025 | -324.65 Mn |
| Dec 31, 2024 | -311,175.59 Bn |
| Jun 30, 2024 | -294.76 Mn |
| Dec 31, 2023 | -277,751.48 Bn |
| Jun 30, 2023 | -262,913.91 Bn |
| Dec 31, 2022 | -258,805.11 Bn |
| Jun 30, 2022 | -226,476.06 Bn |
| Dec 31, 2021 | 336.10 Mn |
| Jun 30, 2021 | -142.85 Mn |
| Dec 31, 2020 | -105.66 Mn |
| Dec 31, 2019 | -63.26 Mn |